We analyzed a sample of the product (3) by nonreducing SDS-PAGE (Figure 6)

We analyzed a sample of the product (3) by nonreducing SDS-PAGE (Figure 6). was monitored at A354. We evaluated epitope immunoreactivity for each mAb in the construct. Flow cytometry demonstrated binding of the bispecific Carbamazepine construct to BMMSCs Carbamazepine that was competed by free anti-CD90 mAb, verifying that modification and cross-linking were not detrimental to the anti-CD90 complementarity-determining region. Similarly, ELISA-based assays demonstrated bispecific antibody binding to plastic-immobilized recombinant MLC1. Excess anti-MLC1 mAb competed for bispecific antibody binding. Finally, the anti-CD90 anti-MLC1 bispecific antibody construct induced BMMSC adhesion to plastic-immobilized MLC1 that was resistant to shear stress, as measured in parallel-plate flow chamber assays. We used mAbs that bind both human antigens and the respective pig homologues. Thus, the anti-CD90 anti-MLC1 bispecific antibody may be used in large animal studies of acute myocardial infarction and may provide a starting point for clinical studies. INTRODUCTION Stem cell therapy is a promising therapeutic modality for restoring cardiac function in cardiovascular disease.1, 2 The preclinical findings that bone marrowCderived multipotent stromal cells (BMMSCs) effect tissue repair3 and have immunomodulatory activity4 have led to the clinical testing Carbamazepine of these cells in the treatment of a variety of diseases.5 Furthermore, in a PROCR pig model of myocardial infarction, BMMSC engraftment and differentiation has been correlated with improved heart function.6 However, the effectiveness of this therapy may be limited by low rates of cellular retention and engraftment in areas of cell delivery, even when cells are applied directly to the myocardium.7, 8 One approach to address this issue is to target stem cells to ischemic tissue by creating a bispecific antibody that can bind to antigens specific for the stem cell and to the target tissue. This approach has been used in cancer therapy to target immune effector cells to tumor cells,9 and catumaxomab, a first-generation bispecific antibody, has been approved recently in Europe for treating malignant ascites.10 Lee and colleagues11 have applied this methodology to cardiac stem cell therapy by generating a bispecific antibody construct to direct hematopoietic stem cells to infarcted myocardium in rodents.11, 12 In this construct, the tissue-targeting arm uses a monoclonal antibody (mAb) specific for myosin light chain 1 (MLC1) (mAb MLM508), which is found within the interstitial tissue of damaged hearts13 and serves as an antigen marker for injured myocardium.14-16 The other arm of the construct for binding hematopoietic stem cells is composed of a mAb to CD45,11, 12 which is a common leukocyte antigen17 found on CD34+ hematopoietic stem cells.18 In the present study, we have created a novel bispecific antibody for targeting BMMSCs to injured myocardium. The tissue-targeting arm of our reagent comprises the mAb MLM508 described above, which reacts with both pig and human MLC1.19 Because BMMSCs do not express CD4520 [the antigen used in the construct made by Lee and colleagues],11, 12 the stem-cell binding arm of our antibody was composed of mAb5E10, which recognizes the phenotypic cell surface marker CD90 (Thy-1)21 found on BMMSCs. mAb 5E10 recognizes both pig and human BMMSCs.22 To generate an anti-CD90 anti-MLC1 bispecific antibody construct, we used methods that labeled one mAb with a 6-hydrazinonicotinamide moiety a conventional NHS-ester. The second mAb in the bispecific construct was modified with a pegylated 4-formylbenzamide moiety, a pentafluorophenyl ester. Formation of the bis-aryl hydrazone, which is readily monitored by UV-vis Carbamazepine spectroscopy, was rapid and precluded formation of homodimeric antibody products, which can occur with the use of other.